CARBETOCIN FERRING (carbetocin, room temperature-stable formulation)

CARBETOCIN FERRING (carbetocin, room-temperature stable formulation) is Ferring’s long-acting, oxytocin analogue that is used to prevent uterine haemorrhage due to postpartum uterine atony.

CARBETOCIN FERRING is intended for use by Health Care Professionals only and is administered via a single intravenous or intramuscular injection as soon as possible after delivery of the infant and preferably before the delivery of the placenta. CARBETOCIN FERRING is contraindicated for use in pregnancy and labour before delivery of the infant, induction or augmentation of labour, serious cardiovascular disorders, epilepsy, renal or hepatic disorders, hypersensitivity to carbetocin, oxytocin or any of the excipients according to the composition.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations.

For specific product information please consult the summary of product characteristics (SmPC) or the patient information leaflet. For advice on medical issues please consult your local medical practitioner.

To know more about Ferring’s commitment to reduce maternal and infant mortality please visit our Safe Birth page.

CHORAGON® / BREVACTID® (u-hCG)

CHORAGON (u-hCG) is a glycopeptide hormone administered by intramuscular injection and used to control the timing of ovulation.

HCG mimics the action of LH and is the drug of choice to trigger ovulation following follicular stimulation and development. It is also used in combination with MENOPUR / MENOGON to stimulate spermatogenesis in male infertility due to hypogonadism.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

GONAPEPTYL® / DECAPEPTYL® daily (triptorelin acetat)

GONAPEPTYL / DECAPEPTYL* (triptorelin acetat) is a solution for injection containing 0.1 mg/1 ml of triptorelin acetate (per prefilled syringe). It is indicated for the down regulation of the pituitary before and during controlled ovarian hyperstimulation in assisted reproduction techniques.

DECAPEPTYL in men suppresses the action of testosterone and oestrogen making it a standard therapy for diseases that depend on hormones, such as prostate cancer where it slows the development of the cancer.

(*In certain markets, the DECAPEPTYL trademark is owned by Debiopharm International S.A. and is not associated with Ferring.)

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

LUTINUS® / ENDOMETRIN® (progesterone)

LUTINUS / ENDOMETRIN (progesterone) is a vaginal tablet containing 100 mg progesterone per tablet. It
is indicated for luteal support as part of an Assisted Reproductive Technology (ART) treatment programme
for infertile women.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience
in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject
to further local variations. For specific product information please consult the summary of product characteristics (SPC). For
advice on medical issues please consult your local medical practitioner.

LUTREPULSE® / LUTRELEF® (gonadorelin acetate)

LUTREPULSE® / LUTRELEF® (gonadorelin acetate) is used in replacement therapy of endogenous GnRH-deficiency, for the treatment of infertility in women and men. This can induce sexual development, follicle maturation and ovulation in women whose normal secretion of GnRH (and therefore of FSH and LH) is affected. It can also be used in men to induce sperm production.

LUTREPULSE® / LUTRELEF® is administered automatically using an injection device (Pod). The Pod comes together with the Manager, a remote control used to set up the Pod and monitor its function.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

MENOPUR® / MENOGON® / REPRONEX® (HP-hMG)

MENOPUR (HP-hMG) is a highly purified human menopausal gonadotrophin containing a 1:1 ratio of FSH (follicle stimulating hormone) and LH (luteinizing hormone) bioactivity.

MENOPUR has indications for treatment of female and male infertility in the following groups of patients:

• Anovulatory women: MENOPUR can be used to stimulate follicle development in amenorrhoeic patients

• Women undergoing superovulation within a medically assisted fertilisation programme: MENOPUR can be used to induce multiple follicular development in patients undergoing an assisted conception technique such as in-vitro fertilisation (IVF).

• Hypogonadotrophic hypogonadism in men: MENOPUR may be given in combination with human chorionic gonadotrophin (e.g. CHORAGON®) for the stimulation of spermatogenesis.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

NORPROLAC® (quinagolide hydrochloride)

NORPROLAC (quinagolide hydrochloride) is a selective, D2 dopamine agonist that is used for the treatment of elevated levels of prolactin. The secretion of prolactin is reduced by the neurotransmitter dopamine which acts on prolactin-secreting cells in the pituitary gland. NORPROLAC mimics the action of dopamine in the pituitary to reduce prolactin levels. NORPROLAC is provided in tablet form for oral administration.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

PABAL® / DURATOCIN® / LONACTENE® / DURATOBAL® (carbetocin)

PABAL / DURATOCIN / LONACTENE / DURATOBAL (carbetocin) is Ferring’s long-acting, oxytocin analogue that is used to prevent haemorrhage following caesarean section.

Haemorrhaging from the uterus can occur following an incomplete abortion, a caesarean section or following the final stage of labour, once the placenta has been expelled, due to insufficient tone in the uterus (atony).

PABAL is administered via a single intravenous injection before or after the delivery of the placenta.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

PROPESS® / CERVIDIL® (dinoprostone)

PROPESS® / CERVIDIL®* (dinoprostone) is indicated for initiation of cervical ripening in patients at term.

PROPESS is administered through a vaginal insert contained in a polyester pouch with a withdrawal tape.
PROPESS releases dinoprostone at a constant and controlled rate. If, for any reason, treatment must be interrupted, the vaginal insert can quickly and easily be pulled out.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

REKOVELLE®

REKOVELLE® (follitropin delta) is the first recombinant follicle stimulating hormone (FSH) derived from a human cell line.

REKOVELLE® is indicated for controlled ovarian stimulation (COS) for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.

REKOVELLE® is administered using an individualised dosing regimen according to a woman’s serum anti-Müllerian hormone (AMH) level and her body weight.

AMH is a biomarker used to assess ovarian reserve and predict ovarian response to COS. AMH levels are measured using a companion diagnostic, the Elecsys® AMH Plus immunoassay from Roche.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.

TRACTOCILE® (atosiban)

TRACTOCILE (atosiban) is a treatment indicated to delay imminent pre-term birth, which is the main cause of death and disability in new-born infants. The active ingredient, atosiban, is an oxytocin/vasopressin antagonist that blocks the action of oxytocin and is able to prevent uterine contractions and relax the uterus.

TRACTOCILE is administered by an intravenous infusion in three successive stages to delay imminent preterm birth.

Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.